एफाविरेंज़ और पिमावैनसेरिन का इंटरैक्शन

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID.

Intervention: Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID [see Dosage and Administration (2.3) ] .

Strong CYP3A4 Inhibitors: Reduce NUPLAZID dose to 10 mg once daily.

Strong CYP3A4 Inhibitors Clinical Impact: Concomitant use of NUPLAZID with a strong CYP3A4 inhibitor increases pimavanserin exposure [see Clinical Pharmacology (12.3) ] .

Intervention: If NUPLAZID is used with a strong CYP3A4 inhibitor, reduce the dosage of NUPLAZID [see Dosage and Administration (2.3) ].

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval.